Literature DB >> 18544959

Squamous cell carcinoma antigen in patients with locally advanced cervical carcinoma undergoing preoperative radiochemotherapy: association with pathological response to treatment and clinical outcome.

Gabriella Ferrandina1, Gabriella Macchia, Francesco Legge, Francesco Deodato, Franca Forni, Cinzia Digesù, Vito Carone, Alessio G Morganti, Giovanni Scambia.   

Abstract

OBJECTIVE: We investigated the role of squamous cell carcinoma (SCC) at presentation (pre-SCC) and after treatment (post-SCC) as predictor of pathological response and outcome in locally advanced cervical cancer (LACC) patients undergoing preoperative chemoradiation.
METHODS: One hundred and twenty-three consecutive LACC patients underwent preoperative chemoradiation including cisplatin and 5-fluorouracil plus external radiotherapy to the whole pelvic region. Clinical responders underwent radical surgery. SCC levels were expressed in nanograms/milliliter.
RESULTS: Ninety-five of 123 (77.2%) and 15/113 (13.3%) cases were classified as having high pre-SCC and high post-SCC levels. Complete pathological response was documented in 51 cases (41.5%), while persistence of microscopic foci was shown in 40 cases (32.5%). In the univariate analysis, FIGO (International Federation of Gynecology and Obstetrics) stage, clinical response to treatment and post-SCC levels were associated with pathological response to chemoradiation. In the multivariate analysis, only clinical response to treatment and post-SCC levels retained an independent role as predictors of pathological response to treatment. Cases with high post-SCC status had a shorter disease-free survival than cases with low post-SCC levels (p = 0.028). In the multivariate analysis, lack of a pathological complete response/persistence of microscopic foci to treatment retained an independent negative prognostic role for disease-free survival.
CONCLUSIONS: Post-SCC identifies LACC patients with a poor chance of pathological response to chemoradiation and an unfavorable outcome. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18544959     DOI: 10.1159/000138979

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  5 in total

1.  In Vitro Selection of a DNA Aptamer by Cell-SELEX as a Molecular Probe for Cervical Cancer Recognition and Imaging.

Authors:  Jine Wang; Tian Gao; Yu Luo; Zhili Wang; Yajie Zhang; Ye Zhang; Yuanyuan Zhang; Renjun Pei
Journal:  J Mol Evol       Date:  2019-01-19       Impact factor: 2.395

2.  Clinical value of serum HMGB1 levels in early detection of recurrent squamous cell carcinoma of uterine cervix: comparison with serum SCCA, CYFRA21-1, and CEA levels.

Authors:  Xiugui Sheng; Xuelian Du; Xiaoling Zhang; Dapeng Li; Chunhua Lu; Qinshui Li; Zhifang Ma; Quqing Song; Cong Wang
Journal:  Croat Med J       Date:  2009-10       Impact factor: 1.351

3.  A preliminary investigation into textural features of intratumoral metabolic heterogeneity in (18)F-FDG PET for overall survival prognosis in patients with bulky cervical cancer treated with definitive concurrent chemoradiotherapy.

Authors:  Kung-Chu Ho; Yu-Hua Dean Fang; Hsiao-Wen Chung; Tzu-Chen Yen; Tsung-Ying Ho; Hung-Hsueh Chou; Ji-Hong Hong; Yi-Ting Huang; Chun-Chieh Wang; Chyong-Huey Lai
Journal:  Am J Nucl Med Mol Imaging       Date:  2016-07-06

4.  Development of a novel biomarker model for predicting preoperative lymph node metastatic extent in esophageal squamous cell carcinoma1.

Authors:  Zhao Ma; Xianxian Wu; Bo Xu; Hongjing Jiang; Peng Tang; Jie Yue; Mingquan Ma; Chuangui Chen; Hongdian Zhang; Zhentao Yu
Journal:  Oncotarget       Date:  2017-11-11

5.  The role of squamous cell carcinoma antigen as a prognostic and predictive factor in carcinoma of uterine cervix.

Authors:  Bae Kwon Jeong; Doo Ho Choi; Seung Jae Huh; Won Park; Duk Soo Bae; Byoung-Gie Kim
Journal:  Radiat Oncol J       Date:  2011-09-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.